aTYR PHARMA INC Operating Lease, Right-of-Use Asset, Amortization Expense
aTYR PHARMA INC (ATYR) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $469.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-07
- aTYR PHARMA INC operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $237.00K, a 7.24% increase year-over-year.
- aTYR PHARMA INC operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $232.00K, a 7.41% increase year-over-year.
- aTYR PHARMA INC operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $228.00K.
- aTYR PHARMA INC operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $224.00K, a 6.67% increase year-over-year.
- aTYR PHARMA INC operating lease, right-of-use asset, amortization expense for fiscal 2025 was $889.00K, a 6.85% increase from fiscal 2024.
- aTYR PHARMA INC operating lease, right-of-use asset, amortization expense for fiscal 2024 was $832.00K, a 61.28% decline from fiscal 2023.
- aTYR PHARMA INC operating lease, right-of-use asset, amortization expense for fiscal 2023 was $2.15M, a 46.89% increase from fiscal 2022.
- aTYR PHARMA INC operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.46M, a 76.48% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $237.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $469.00K 10-Q · filed 2026-08-07 | $697.00K derived: sum of 3 quarters · filed 2026-08-07 | $921.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $232.00K 10-Q · filed 2026-05-15 | $460.00K derived: sum of 2 quarters · filed 2026-05-15 | $684.00K derived: sum of 3 quarters · filed 2026-05-15 | $905.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $228.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $452.00K derived: sum of 2 quarters · filed 2026-03-05 | $673.00K derived: sum of 3 quarters · filed 2026-08-07 | $889.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $224.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $445.00K derived: sum of 2 quarters · filed 2026-08-07 | $661.00K 10-Q · filed 2025-11-06 | $485.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $221.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $437.00K 10-Q · filed 2026-08-07 | $261.00K derived: sum of 3 quarters · filed 2026-08-07 | $471.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $216.00K 10-Q · filed 2026-05-15 | $40.00K derived: sum of 2 quarters · filed 2026-05-15 | $250.00K derived: sum of 3 quarters · filed 2026-05-15 | $456.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$176.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $34.00K derived: sum of 2 quarters · filed 2026-03-05 | $240.00K derived: sum of 3 quarters · filed 2026-03-05 | $832.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $210.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $416.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.01M 10-Q · filed 2025-11-06 | $1.24M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $206.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $798.00K 10-Q · filed 2025-08-07 | $1.03M derived: sum of 3 quarters · filed 2026-03-05 | $1.85M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $592.00K 10-Q · filed 2025-05-07 | $824.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.64M derived: sum of 3 quarters · filed 2026-03-05 | $2.07M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $232.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.05M derived: sum of 2 quarters · filed 2026-03-05 | $1.47M derived: sum of 3 quarters · filed 2026-03-05 | $2.15M 10-K · filed 2026-03-05 |
| 2023-09-30 | $817.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.24M derived: sum of 2 quarters · filed 2024-11-07 | $1.92M 10-Q · filed 2024-11-07 | $2.58M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $425.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.10M 10-Q · filed 2024-08-13 | $1.76M derived: sum of 3 quarters · filed 2025-03-13 | $2.12M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $675.00K 10-Q · filed 2024-05-02 | $1.33M derived: sum of 2 quarters · filed 2025-03-13 | $1.70M derived: sum of 3 quarters · filed 2025-03-13 | $1.92M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $658.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.02M derived: sum of 2 quarters · filed 2025-03-13 | $1.25M derived: sum of 3 quarters · filed 2025-03-13 | $1.46M 10-K · filed 2025-03-13 |
| 2022-09-30 | $365.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $588.00K derived: sum of 2 quarters · filed 2023-11-09 | $805.00K 10-Q · filed 2023-11-09 | $1.02M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $223.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $440.00K 10-Q · filed 2023-08-09 | $652.00K derived: sum of 3 quarters · filed 2024-03-14 | $858.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $217.00K 10-Q · filed 2023-05-09 | $429.00K derived: sum of 2 quarters · filed 2024-03-14 | $635.00K derived: sum of 3 quarters · filed 2024-03-14 | $870.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $212.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $418.00K derived: sum of 2 quarters · filed 2024-03-14 | $653.00K derived: sum of 3 quarters · filed 2024-03-14 | $829.00K 10-K · filed 2024-03-14 |
| 2021-09-30 | $206.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $441.00K derived: sum of 2 quarters · filed 2022-11-14 | $617.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $235.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $411.00K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $176.00K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $697.00K 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |